Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) has been named a co-applicant in a competitive Terry Fox Research Institute grant awarded to advance Onco-Innovations’ SynoGraph™ oncology platform, according to a September 22 announcement. The project, titled “Causal AI to Predict First-in-Human Clinical Outcomes from Preclinical and Real-World Clinico-Genomic Data,” brings together academic and industry partners to explore how artificial intelligence can improve predictions of first-in-human clinical outcomes using preclinical and real-world clinico-genomic data.
Redwood AI, developer of an AI-powered platform for real-world applications across multiple critical industries, will contribute proprietary data integration and physicochemical modelling methods to expand SynoGraph’s predictive capabilities. The company joins Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) as lead applicant, along with the Michael Smith Genome Sciences Centre and the Centre de recherche du CHU de Québec-Université Laval as co-applicants. The collaboration underscores the growing role of AI in oncology research and the importance of cross-sector partnerships in driving innovation.
The grant supports a project with an estimated budget of $3.5 million and reimburses eligible costs up to 25% of that amount. Academic partners will provide clinico-genomic and imaging data for research using federated learning, which is intended to support analysis while protecting data privacy. This approach allows researchers to leverage distributed datasets without compromising patient confidentiality, a critical consideration in cancer research.
For investors and industry observers, the project highlights Redwood AI’s expanding footprint in the healthcare sector and its ability to apply its AI expertise to high-impact challenges. The latest news and updates relating to RDWCF are available in the company’s newsroom at https://ibn.fm/RDWCF. The project’s focus on causal AI—a branch of AI that seeks to understand cause-and-effect relationships—could lead to more accurate predictions of how cancer therapies will perform in humans, potentially reducing the time and cost of drug development.
The Terry Fox Research Institute is a leading Canadian organization dedicated to cancer research, and its backing of this project signals confidence in the consortium’s approach. If successful, SynoGraph could become a valuable tool for pharmaceutical companies and researchers, enabling better prioritization of drug candidates and more efficient clinical trials. This news is particularly relevant as the demand for precision medicine grows, with AI poised to play a central role in analyzing complex biological data.
Redwood AI’s participation also demonstrates the increasing convergence of AI and life sciences, a trend that is attracting significant investment and attention. The company’s proprietary methods in data integration and physicochemical modelling are expected to enhance SynoGraph’s ability to integrate diverse data types, from preclinical studies to real-world clinical data. As the project progresses, stakeholders will be watching closely for milestones that could validate the platform’s potential.
For more information about Redwood AI Corp., visit Redwood AI Corp.. The announcement was disseminated by AINewsWire, a specialized communications platform focused on AI advancements. AINewsWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. The full story can be read at Read More>>.
